Doctor's Data offers scores of distinct tests across key categories:
Allergy & Immunology
Clinical Microbiology

Environmental Exposure/Detoxification
Toxic & Essential Elements


The Roadmap for Clinical Diagnosis:

Celiac Disease vs Non-Celiac Gluten Sensitivity

Celiac Disease - Rule It out

With the disturbing increase in the
incidence of autoimmune disorders
in developed nations, the treatment
of these diseases, including Celiac
Disease (CD) is rapidly becoming
a serious public health issue. CD is
an autoimmune disorder that affects
the small intestine in individuals with
genetic susceptibilities.
In people with CD, the unique trigger
of ingesting gluten, a protein molecule
found in wheat, barley and rye, leads to
an immune attack of the finger-like villi in the
small intestines. When the villi become damaged people cannot absorb nutrients and the body is more prone to malnutrition, vitamin deficiencies and anemia.
Until recently, clinical and technological advances in the laboratory, the criteria for diagnosis of CD was performed by small intestine biopsy to identify characterized inflammatory changes of villi and the intestinal lining. With the advent of of clinical laboratory assays for the serologic markers of the immune response associated with CD, a less invasive method is available to support a diagnosis of CD when considered in conjunction with the patient's symptoms, immune status, diet, genetic predisposition and medical history. These sensitive and specific laboratory assays for the identification and quantitation of the immunoglobulins produced against tissue transglutaminase (tTG) and deamidated gliadin peptide (DGP) are now part of the CD diagnostic algorithm.

 Immunoglobulin A (IgA) anti-tissue transglutaminase (tTG)
antibody is an FDA-cleared biomarker and is the preferred
single test for detection of CD in individuals over age 2.
 (Click image for full sample report)
 If any tTG or DGP markers are found elevated in suspected CD patients, then CD should be strongly considered. Otherwise, Non-Celiac Gluten Sensitivity is the next condition to be considered and examined by the practitioner.

Non-Celiac Gluten Sensitivity - Distinguish the Difference

Non-Celiac Gluten Sensitivity (NCGS) defined as a gluten reaction that is independent of the IgE reactions of wheat allergy and autoantibody reactions of CD, has emerged as a more prominent condition today. In these cases individuals test negative for CD, but often display similar gastrointestinal symptoms, with a prevalence as high as 1 in 13. Historically, gluten sensitivity was determined in individuals via implementing a gluten free elimination diet. Now with the advent of FDA-cleared methods for the gliadin antibodies, a more rapid means exists to obtain an indication of NCGS and renders archaic confirmation through implementation of a gluten-free elimination diet.  Doctor's Data uses FDA-cleared biomarkers to analyze gliadin antibodies that identify and quantify IgA and IgG produced against the whole gliadin molecule, including all of its characterized antigenic epitopes, without compromise in analytical sensitivity.
(Click image for full sample report)
The Roadmap - Positives and Negatives 
The Celiac & Gluten Sensitivity; serum profile from Doctor's Data helps differentiate between CD and gluten sensitivity by evaluating the serum titers of IgA and IgG for tissue transglutaminase (tTG), deamidated gliadin peptide (DGP and gliadin. Further, wheat allergy is assessed by titers of IgE for wheat. All test reports include the CD/Gluten Sensitivity/Wheat Allergy Cascade that provides a roadmap of considerations based upon patient results. The Doctor's Data sister test utilizing blood spot specimen also distinguishes between the need to consider CD and NCGS.

Celiac Disease/Gluten Sensitivity/Wheat Allergy Cascade


The Doctor's Data Difference - Efficacy and Affordability in One Test
One major advantage of the Celiac and Gluten Sensitivity profiles at Doctor's Data is precise analysis in one affordable assay. The Celiac and Gluten Sensitivity profile is available via serum or dried blood spot collection.
Consider the Gut
If you have a patient that suffers from symptoms related to CD or NCGS consider Doctor's Data's expanded menu for assessing the GI microbiome, which may be primary to the cause of symptoms, or secondary to intestinal injury or inflammation. Comprehensive GI assessment can provide information on imbalanced microflora, digestive and inflammatory response, intestinal permeability and other important factors.
Follow the links below to view other suggested Doctor's Data Profiles:
Do you have questions about this or any of our other tests? Click the button below to complete our contact request form and your territory representative will reach out to you shortly.

Want to see the latest research on this topic?
Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterology 2013 108:656–676.

Volta U, Caio G, Tovoli F, De Giorgio R. Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness. Cellular & Molecular Immunology 2013 10, 383–392.

Lau N, et al.  Markers of Celiac Disease and Gluten Sensitivity in Children with Autism.  PLoS One. 2013 Jun 18;8(6):e66155.


Why choose Doctor's Data Inc.?
Doctor's Data, Inc. has provided innovative specialty testing to healthcare practitioners around the world from our advanced CLIA-licensed clinical laboratory since 1972.

A specialist and pioneer in essential and toxic elemental testing, the laboratory provides a wide array of functional testing to aid in decision making and better patient outcomes.  Choose DDI to help you assess and treat heavy metal burden, nutritional deficiencies, gastrointestinal function, cardiovascular risk, liver and metabolic abnormalities, and more. 

DOCTORS DATA, INC. | 3755 Illinois Avenue, St. Charles, IL 60174-2420 USA | 800.323.2784 (US and Canada) | 0871.218.0052 (UK) | +1.630.377.8139 (Global) | +1.630.587.7860 (Fax)